<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ICLUSIG- ponatinib hydrochloride tablet, film coated </strong><br>ARIAD Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG.<br><br> ICLUSIG<span class="Sup">®</span> (ponatinib) tablets for oral use<br> Initial U.S. Approval: 2012</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">VASCULAR OCCLUSION</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span>, and HEPATOTOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span>: Arterial and <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, stenosis of large arterial vessels of the brain, severe <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, and the need for urgent revascularization procedures.  Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>. Interrupt or stop Iclusig immediately for <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>. (<a href="#S5.1">5.1</a>). </span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#S5.2">5.2</a>).</span></li>
<li><span class="Bold">Hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected (<a href="#S2.3">2.3</a>, <a href="#S5.3">5.3</a>).</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless">
<tr>
<td align="left"><a href="#BOX">Boxed Warning</a></td>
<td align="right">12/2013</td>
</tr>
<tr>
<td align="left">Indications and Usage (<a href="#S1">1</a>)</td>
<td align="right">12/2013</td>
</tr>
<tr>
<td align="left">Dosage and Administration (<a href="#S2.1">2.1</a>)</td>
<td align="right">12/2013</td>
</tr>
<tr>
<td align="left">Dosage and Administration (<a href="#S2.5">2.5</a>)</td>
<td align="right">07/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions (<a href="#S5.1">5.1</a>,<a href="#S5.2"> 5.2</a>,<a href="#S5.4"> 5.4</a>,<a href="#S5.6"> 5.6</a>, and<a href="#S5.7"> 5.7</a>)</td>
<td align="right">12/2013</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">VASCULAR OCCLUSION</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span>, and HEPATOTOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span>: Arterial and <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, stenosis of large arterial vessels of the brain, severe <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, and the need for urgent revascularization procedures.  Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>. Interrupt or stop Iclusig immediately for <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>. (<a href="#S5.1">5.1</a>). </span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#S5.2">5.2</a>).</span></li>
<li><span class="Bold">Hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected (<a href="#S2.3">2.3</a>, <a href="#S5.3">5.3</a>).</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Iclusig is a kinase inhibitor indicated for the: </p>
<ul class="Disc">
<li>Treatment of adult patients with T315I-positive <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (Ph+ ALL).</li>
<li>Treatment of adult patients with chronic phase, accelerated phase, or blast phase <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated. (<a href="#S1">1</a>)</li>
</ul>
<p class="Highlighta">These indications are based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig. </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended dose: 45 mg taken orally once daily with or without food (<a href="#S2.1">2.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: 30 mg orally once daily (<a href="#S2.5">2.5</a>)</li>
<li>Modify or interrupt dosing for hematologic and non-hematologic toxicity (<a href="#S2.2">2.2</a>,<a href="#S2.3"> 2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 15 mg and 45 mg (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>None (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: Monitor for high blood pressure and manage as clinically indicated (<a href="#S5.4">5.4</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>: Monitor serum lipase monthly; interrupt or discontinue Iclusig (<a href="#S2.3">2.3</a>,<a href="#S5.5"> 5.5</a>). </li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>: Monitor for symptoms of peripheral and <span class="product-label-link" type="condition" conceptid="441848" conceptname="Cranial nerve disorder">cranial neuropathy</span> (<a href="#S5.6">5.6</a>).</li>
<li>Ocular Toxicity: Conduct comprehensive eye exams at baseline and periodically during treatment (<a href="#S5.7">5.7</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Interrupt Iclusig for serious or severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (<a href="#S5.8">5.8</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>:  Monitor patients for <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>; interrupt, reduce, or discontinue Iclusig (<a href="#S5.9">5.9</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span>:  Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (<a href="#S5.10">5.10</a>,<a href="#S6"> 6</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> may require dose interruption or reduction. Monitor complete blood counts every 2 weeks for 3 months and then monthly and as clinically indicated. Interrupt Iclusig for ANC &lt; 1000/mm<span class="Sup">3</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> &lt; 50,000/ mm<span class="Sup">3</span> (<a href="#S2.2">2.2</a>,<a href="#S5.11"> 5.11</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span>: Ensure adequate hydration and correct elevated uric acid levels prior to initiating therapy with Iclusig (<a href="#S5.12">5.12</a>).</li>
<li>Compromised <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing and <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span>: Temporarily interrupt therapy in patients undergoing major surgical procedures (<a href="#S5.13">5.13</a>).</li>
<li>Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of potential risk to a fetus (<a href="#S5.14">5.14</a>,<a href="#S8.1"> 8.1</a>).</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common non-hematologic adverse reactions (≥ 20%) were <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>. Hematologic adverse reactions included <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<a href="#S6">6</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ARIAD Pharmaceuticals, Inc. at 1-855-55-ARIAD or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Strong CYP3A Inhibitors: Avoid concurrent use, or reduce Iclusig dose if co-administration cannot be avoided (<a href="#S2.4">2.4</a>, <a href="#S7.1">7.1</a>)</li>
<li>Strong CYP3A Inducers: Avoid concurrent use (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">The safety and efficacy of Iclusig in patients less than 18 years of age have not been tested (<a href="#S8.4">8.4</a>). </p></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">VASCULAR OCCLUSION</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span>, and HEPATOTOXICITY</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Modifications for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dose Modifications for Non-Hematologic Adverse Reactions</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Dose Modification for Use With Strong CYP3A Inhibitors</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Dose Modification for Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Hepatotoxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Ocular Toxicity</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Compromised <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing and <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Embryo-Fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Drugs That Are Strong Inhibitors of CYP3A Enzymes</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Drugs That Are Strong Inducers of CYP3A Enzymes</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Drugs That Elevate Gastric pH</a></h2>
<h2><a href="#section-7.4" class="toc">7.4		Drugs That Are Substrates of the P-gp or ABCG2 Transporter Systems</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">VASCULAR OCCLUSION</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span>, and HEPATOTOXICITY</span></h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span>:</span></span></p>
<ul class="Disc">
<li><span class="Bold">Arterial and <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, stenosis of large arterial vessels of the brain, severe <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Monitor for evidence of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>. Interrupt or stop Iclusig immediately for <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>.  A benefit-risk consideration should guide a decision to restart Iclusig therapy (<a href="#S5.1">5.1</a>).</span></li>
</ul>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>:</span></p>
<ul class="Disc"><li><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>, including fatalities, occurred in 8% of Iclusig-treated patients.  Monitor cardiac function.  Interrupt or stop Iclusig for new or worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#S5.2">5.2</a>).</span></li></ul>
<p><span class="Bold">Hepatotoxicity: </span></p>
<ul class="Disc"><li><span class="Bold">Hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected (<a href="#S2.3">2.3</a>, <a href="#S5.3">5.3</a>).</span></li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Iclusig (ponatinib) is a kinase inhibitor indicated for the: </span></p>
<ul class="Disc">
<li style="border-left:1px solid;"><span class="XmChange">Treatment of adult patients with T315I-positive <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (Ph+ALL).</span></li>
<li style="border-left:1px solid;"><span class="XmChange">Treatment of adult patients with chronic phase, accelerated phase, or blast phase <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.</span></li>
</ul>
<p>These indications are based upon response rate <span class="Italics">[see<a href="#S14"> Clinical Studies (14)</a>]</span>. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosing</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The optimal dose of Iclusig has not been identified. In clinical trials, the starting dose of Iclusig was 45 mg administered orally once daily. However, 59%  of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Start dosing with 45 mg once daily. Consider reducing the dose of Iclusig for chronic phase (CP) CML and accelerated phase (AP) CML patients who have achieved a major cytogenetic response.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Consider discontinuing Iclusig if response has not occurred by 3 months (90 days).</span></p>
<p>Iclusig may be taken with or without food. Tablets should be swallowed whole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Modifications for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Suggested dose modifications for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC* less than 1.0 × 10<span class="Sup">9</span>/L) and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet less than 50 × 10<span class="Sup">9</span>/L) that are unrelated to <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> are summarized in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Suggested Dose Modifications for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></span></caption>
<col align="left" valign="middle" width="30%">
<col align="left" valign="top" width="70%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>ANC = absolute neutrophil count</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" rowspan="6">ANC<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> &lt; 1 × 10<span class="Sup">9</span>/L<br>or<br>platelet &lt; 50 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="left">First occurrence:</td>
</tr>
<tr class="Botrule"><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume initial 45 mg dose after recovery to ANC ≥ 1.5 × 10<span class="Sup">9</span>/L and platelet ≥ 75 × 10<span class="Sup">9</span>/L</li></ul></td></tr>
<tr><td class="Rrule" align="left">Second occurrence:</td></tr>
<tr class="Botrule"><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 30 mg after recovery to ANC ≥ 1.5 × 10<span class="Sup">9</span>/L and platelet ≥ 75 × 10<span class="Sup">9</span>/L</li></ul></td></tr>
<tr><td class="Rrule" align="left">Third occurrence:</td></tr>
<tr class="Last"><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 15 mg after recovery to ANC ≥ 1.5 × 10<span class="Sup">9</span>/L and platelet ≥ 75 × 10<span class="Sup">9</span>/L</li></ul></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dose Modifications for Non-Hematologic Adverse Reactions</h2>
<p class="First">If a serious non-hematologic adverse reaction occurs, modify the dose or interrupt treatment. Do not restart Iclusig in patients with arterial or venous occlusive reactions unless the potential benefit outweighs the risk of recurrent arterial or <span class="product-label-link" type="condition" conceptid="4145867" conceptname="Venous occlusion">venous occlusions</span> and the patient has no other treatment options. For serious reactions other than arterial or <span class="product-label-link" type="condition" conceptid="4145867" conceptname="Venous occlusion">venous occlusion</span>, do not restart Iclusig until the serious event has resolved or the potential benefit of resuming therapy is judged to outweigh the risk.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Italics">Hepatic Toxicity </span></p>
<p>Recommended modifications for hepatic toxicity are summarized in Table 2.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Recommended Dose Modifications for Hepatic Toxicity</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>ULN =  Upper Limit of Normal for the lab</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" rowspan="6">Elevation of liver transaminase &gt; 3 × ULN<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> (Grade 2 or higher)</td>
<td class="Rrule" align="left">Occurrence at 45 mg:</td>
</tr>
<tr><td class="Rrule" align="left"><ul class="Disc">
<li>Interrupt Iclusig and monitor hepatic function</li>
<li>Resume Iclusig at 30 mg after recovery to ≤ Grade 1 (&lt; 3 × ULN)</li>
</ul></td></tr>
<tr><td class="Rrule" align="left">Occurrence at 30 mg:</td></tr>
<tr><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 15 mg after recovery to ≤ Grade 1</li></ul></td></tr>
<tr><td class="Rrule" align="left">Occurrence at 15 mg:</td></tr>
<tr class="Botrule"><td class="Rrule" align="left"><ul class="Disc"><li>Discontinue Iclusig</li></ul></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<br>Elevation of AST or ALT ≥ 3 × ULN concurrent with an elevation of bilirubin &gt; 2 × ULN and alkaline phosphatase  &lt; 2 × ULN</td>
<td class="Rrule" align="left">Discontinue Iclusig</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> and Elevation of Lipase</span></p>
<p>Recommended modifications for pancreatic adverse reactions are summarized in Table 3.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table  3: Recommended Dose Modifications for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> and Elevation of Lipase</span></caption>
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="70%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>ULN = Upper Limit of Normal for the lab</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Asymptomatic Grade 1 or 2 elevation of serum lipase</td>
<td class="Rrule" align="left">Consider interruption or dose reduction of Iclusig</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6">Asymptomatic Grade 3 or 4 elevation of lipase (&gt; 2 × ULN<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>) or asymptomatic radiologic <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (Grade 2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</td>
<td class="Rrule" align="left">Occurrence at 45 mg:</td>
</tr>
<tr><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 30 mg after recovery to ≤ Grade 1 (&lt; 1.5 × ULN)</li></ul></td></tr>
<tr><td class="Rrule" align="left">Occurrence at 30 mg:</td></tr>
<tr><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 15 mg after recovery to ≤ Grade 1</li></ul></td></tr>
<tr><td class="Rrule" align="left">Occurrence at 15 mg:</td></tr>
<tr class="Botrule"><td class="Rrule" align="left"><ul class="Disc"><li>Discontinue Iclusig</li></ul></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6">Symptomatic Grade 3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></td>
<td class="Rrule" align="left">Occurrence at 45 mg:</td>
</tr>
<tr><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 30 mg complete resolution of symptoms and after recovery of lipase elevation to ≤ Grade 1</li></ul></td></tr>
<tr><td class="Rrule" align="left">Occurrence at 30 mg:</td></tr>
<tr><td class="Rrule" align="left"><ul class="Disc"><li>Interrupt Iclusig and resume at 15 mg after complete resolution of symptoms and after recovery of lipase elevation to ≤ Grade 1</li></ul></td></tr>
<tr><td class="Rrule" align="left">Occurrence at 15 mg:</td></tr>
<tr class="Botrule"><td class="Rrule" align="left"><ul class="Disc"><li>Discontinue Iclusig</li></ul></td></tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Grade 4 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></td>
<td class="Rrule" align="left">Discontinue Iclusig</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Dose Modification for Use With Strong CYP3A Inhibitors</h2>
<p class="First">The recommended dose should be reduced to 30 mg once daily when administering Iclusig with strong CYP3A inhibitors <span class="Italics">[see<a href="#S7.1"> Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Dose Modification for Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended starting dose is 30 mg once daily in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A, B, or C) <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">15 mg and 45 mg round, white, film-coated tablets.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Arterial and <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and occlusions, including fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, stenosis of large arterial vessels of the brain, severe <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, and the need for urgent revascularization procedures have occurred in at least 27% of Iclusig-treated patients from the phase 1 and phase 2 trials.  Iclusig can cause fatal and life-threatening <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> within 2 weeks of starting treatment.  Iclusig can also cause recurrent or multi-site <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In the dose-escalation (phase 1) clinical trial, 48% (31/65) of patients with CML or Ph+ ALL developed vascular occlusive events. The median time to onset of the first <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> event was 5 months.  Iclusig can cause fatal and life-threatening <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> in patients treated at dose levels as low as 15 mg per day.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events.  <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular occlusion</span> adverse events were more frequent with increasing age and in patients with prior history of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (see<a href="#table4"> Table 4</a>).</span></p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span> Incidence in Iclusig-Treated Patients in Phase 2 Trial According to Risk Categories</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center"><span class="XmChange">Prior history of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span></span></th>
<th class="Rrule" align="center">No history of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span></th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="XmChange">Age: 49 or younger</span></td>
<td class="Rrule" align="center">18%<br>(6/33)</td>
<td class="Rrule" align="center">12%<br>(13/112)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">Age: 50 to 74 years</span></td>
<td class="Rrule" align="center">33%<br>(50/152)</td>
<td class="Rrule" align="center">18%<br>(20/114)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">Age: 75 and older</span></td>
<td class="Rrule" align="center">56%<br>(14/25)</td>
<td class="Rrule" align="center">46%<br>(6/13)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">All age groups</span></td>
<td class="Rrule" align="center">33%<br>(70/210)</td>
<td class="Rrule" align="center">16%<br>(39/239)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="middle"><span class="XmChange">Total</span></td>
<td class="Rrule" align="center" colspan="2">24%<br>(109/449)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4162038" conceptname="Occlusion of artery">Arterial Occlusion</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4162038" conceptname="Occlusion of artery">Arterial occlusion</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> occurred in at least 20% (91/449) of Iclusig-treated patients with some patients experiencing events of more than one type. Patients have required revascularization procedures (cerebrovascular, coronary, and peripheral arterial) due to <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> from Iclusig.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cardiac <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>, including fatal and life-threatening <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="316995" conceptname="Coronary occlusion">coronary artery occlusion</span> has occurred in 12% (55/449) of Iclusig-treated patients. Patients have developed <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> concurrent or subsequent to the myocardial ischemic event.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Cerebrovascular occlusion, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, has occurred in 6% (27/449) of Iclusig-treated patients. Iclusig can cause stenosis over multiple segments in major arterial vessels that supply the brain (e.g., carotid, vertebral, middle cerebral artery).</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Peripheral arterial occlusive events, including fatal mesenteric artery occlusion and life-threatening peripheral arterial disease, have occurred in 8% (36/449) of Iclusig-treated patients. Patients have developed digital or distal extremity <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and have required amputations.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Clinicians should consider whether the benefits of Iclusig treatment are expected to exceed the risks of therapy. In patients suspected of developing arterial thrombotic events, interrupt or stop Iclusig. A benefit-risk consideration should guide a decision to restart Iclusig therapy. <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> occurred in 5% (23/449) of Iclusig-treated patients, including deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (8 patients), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (6 patients), <span class="product-label-link" type="condition" conceptid="442058" conceptname="Superficial thrombophlebitis in pregnancy and the puerperium">superficial thrombophlebitis</span> (3 patients), and <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span> (2 patients). Consider dose modification or discontinuation of Iclusig in patients who develop serious <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Fatal and serious <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> occurred in 5% of Iclusig-treated patients (N =22).  Eight percent of patients (N= 35) experienced any grade of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>.  Monitor patients for signs or symptoms consistent with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and treat as clinically indicated, including interruption of Iclusig.  Consider discontinuation of Iclusig in patients who develop serious <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span><span class="Italics"> [see<a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Hepatotoxicity</h2>
<p class="First">Iclusig can cause hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">Fulminant hepatic failure</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> occurred in an Iclusig-treated patient within one week of starting Iclusig. Two additional fatal cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> also occurred. The fatal cases occurred in patients with blast phase (BP) CML or Ph+ ALL. Severe hepatotoxicity occurred in all disease cohorts.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (ALT) or <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (AST) elevation was 56% (all grades) and 8% (grade 3 or 4). Iclusig treatment may result in elevation in ALT, AST, or both. ALT or AST elevation was not reversed by the date of last follow-up in 5% of patients.</p>
<p>Monitor liver function tests at baseline, then at least monthly or as clinically indicated. Interrupt, reduce or discontinue Iclusig as clinically indicated <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Treatment-emergent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> occurred in 67% of patients (300/449). Eight patients (2%) treated with Iclusig in clinical trials experienced treatment-emergent symptomatic <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> as a serious adverse reaction, including  <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. Patients may require urgent clinical intervention for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> associated with <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> <span class="Italics">[see<a href="#S6"> Adverse Reactions (6)</a>]</span>. In patients with baseline systolic BP&lt;140 mm Hg and baseline diastolic BP&lt;90mm Hg, 78% (220/282) experienced treatment-emergent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; 49% (139/282) developed Stage 1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (defined as systolic BP≥140 mm Hg or diastolic BP≥90 mm Hg) while 29% developed Stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (defined as systolic BP≥160 mm Hg or diastolic BP≥100 mm Hg). In 131 patients with Stage 1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> at baseline, 61% (80/131) developed Stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor and manage blood pressure elevations during Iclusig use and treat <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> to normalize blood pressure.  Interrupt, dose reduce, or stop Iclusig if <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is not medically controlled.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">Clinical <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurred in 6% (28/449) of patients (5% grade 3) treated with Iclusig. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> resulted in discontinuation or treatment interruption in 6% of patients (25/449). Twenty-two of the 28 cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> resolved within 2 weeks with dose interruption or reduction. The incidence of treatment-emergent lipase elevation was 41%.</p>
<p>Check serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated.  Consider additional serum lipase monitoring in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>. Dose interruption or reduction may be required. In cases where lipase elevations are accompanied by abdominal symptoms, interrupt treatment with Iclusig and evaluate patients for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a>]. </span> Do not consider restarting Iclusig until patients have complete resolution of symptoms and lipase levels are less than 1.5 × ULN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Peripheral and <span class="product-label-link" type="condition" conceptid="441848" conceptname="Cranial nerve disorder">cranial neuropathy</span> have occurred in Iclusig-treated patients.  Overall, 13% (59/449) of Iclusig-treated patients experienced a <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> event of any grade (2%, grade 3/4).  In clinical trials, the most common peripheral neuropathies reported were <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (4%, 18/449), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (4%, 17/449), <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> (2%, 11/449), and <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span> (1%, 5/449). <span class="product-label-link" type="condition" conceptid="441848" conceptname="Cranial nerve disorder">Cranial neuropathy</span> developed in 1% (6/449) of Iclusig-treated patients (&lt;1% grade 3/4).  </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Of the patients who developed <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, 31% (20/65) developed <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> during the first month of treatment. Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, such as <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, a <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Consider interrupting Iclusig and evaluate if <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> is suspected.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Ocular Toxicity</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious ocular toxicities leading to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> have occurred in Iclusig-treated patients. Retinal toxicities including <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">retinal vein occlusion</span>, and <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span> occurred in 3% of Iclusig-treated patients.  Conjunctival or corneal irritation, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> occurred in 13% of patients.  Visual blurring occurred in 6% of patients.  Other ocular toxicities include <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>, and <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span>. Conduct comprehensive eye exams at baseline and periodically during treatment<span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a>]</span>. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events, including fatalities, occurred in 5% (22/449) of patients treated with Iclusig. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> occurred in 24% of patients. The incidence of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events was higher in patients with AP-CML, BP-CML, and Ph+ ALL. <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> were the most commonly reported serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Most hemorrhagic events, but not all, occurred in patients with grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> <span class="Italics">[</span><span class="Italics">see<a href="#S5.11"> Warnings and Precautions (5.11)</a>]</span>. Interrupt Iclusig for serious or severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and evaluate <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> events judged as serious occurred in 3% (13/449) of patients treated with Iclusig. One instance of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">brain edema</span> was fatal. Serious <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events in more than 1 patient included: <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> (6/449, 1%), <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (5/449, 1%), and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (2/449, &lt;1%).</p>
<p>In total, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> occurred in 23% of the patients. The most common <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> events were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (16%), <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> (7%), and <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> (3%).</p>
<p>Monitor patients for <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and manage patients as clinically indicated. Interrupt, reduce, or discontinue Iclusig as clinically indicated <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span></h2>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> that led to a requirement for pacemaker implantation occurred in 1% (3/449) of  Iclusig-treated patients. The cardiac rhythms (1 case each) identified were <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>, <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span>, and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and pauses. Advise patients to report signs and symptoms suggestive of slow heart rate (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>). Interrupt Iclusig and evaluate.</p>
<p>Supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span> occurred in 5% (25/449) of Iclusig-treated patients. <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> was the most common supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span> and occurred in 20 patients. The other supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span> were <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> (4 patients), <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (4 patients), and <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> (1 patient). For 13 patients, the event led to hospitalization. Advise patients to report signs and symptoms of rapid heart rate (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>). Interrupt Iclusig and evaluate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Severe (grade 3 or 4) <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurred in 48% (215/449) of patients treated with Iclusig. The incidence of these events was greater in patients with AP-CML, BP-CML, and Ph+ALL than in patients with CP-CML. Obtain complete blood counts every 2 weeks for the first 3 months and then monthly or as clinically indicated, and adjust the dose as recommended <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First">Two patients (&lt;1%) treated with Iclusig developed serious <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span>. Both cases occurred in patients with advanced CML. <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> occurred in 7% (30/449) of patients; the majority had CP-CML (19 patients). Due to the potential for <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> in patients with advanced disease (AP-CML, BP-CML, or Ph+ ALL), ensure adequate hydration and treat high uric acid levels prior to initiating therapy with Iclusig.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Compromised <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing and <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></h2>
<p class="First">No formal studies of the effect of Iclusig on <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing have been conducted. Based on the mechanism of action <span class="Italics">[see<a href="#S12.1"> Clinical Pharmacology (12.1)</a>]</span>, Iclusig could compromise <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. Serious <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> (<span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>) occurred in one patient 38 days post-cholecystectomy.</p>
<p>Interrupt Iclusig for at least 1 week prior to major surgery. The decision when to resume Iclusig after surgery should be based on clinical judgment of adequate <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Embryo-Fetal Toxicity</h2>
<p class="First">Iclusig can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. Ponatinib caused embryo-fetal toxicity in rats at exposures lower than human exposures at the recommended human dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Advise women to avoid pregnancy while taking Iclusig<span class="Italics"> [see<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The following adverse reactions are discussed in greater detail in other sections of the prescribing information:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusion</span> <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a> and  <a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Hepatotoxicity <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and<a href="#S5.3"> Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3) </a>and<a href="#S5.5"> Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span><span class="Italics"> [see<a href="#S5.6"> Warnings and Precautions (5.6)</a>]</span>
</li>
<li>Ocular Toxicity<span class="Italics"> [see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> <span class="Italics">[see<a href="#S5.8"> Warnings and Precautions (5.8)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> <span class="Italics">[see<a href="#S5.9"> Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span> <span class="Italics">[see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S5.11"> Warnings and Precautions (5.11)</a>]</span>
</li>
</ul>
<p>The adverse reactions described in this section were identified in a single-arm, open-label, international, multicenter trial in 449 patients with CML or Ph+ ALL whose disease was considered to be resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy including those with the BCR-ABL T315I mutation. All patients received a starting dose of 45 mg Iclusig once daily. At the time of analysis, the median duration of treatment with Iclusig was 337 days in patients with CP-CML, 362 days in patients with AP-CML, 89 days in patients with BP-CML, and 81 days in patients with Ph+ ALL. The median dose intensity was 37 mg or 83% of the expected 45 mg dose. The events of arterial <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> reported in Tables 5 and 6 below include data from an additional 13 months of follow-up (median duration of treatment CP-CML: 672 days, AP-CML: 590 days, BP-CML: 89 days, Ph+ ALL: 81 days).</p>
<p>Adverse reactions reported in more than 10% of all patients treated with Iclusig in this trial are presented in Table 5. Overall, the most common non-hematologic adverse reactions (≥ 20%) were <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>.</p>
<p>The rates of treatment-emergent adverse events resulting in discontinuation were 13% in CP-CML, 11% in AP-CML, 15% in BP-CML, and 9% in Ph+ ALL. The most common adverse events that led to treatment discontinuation were <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (4%) and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (1%).</p>
<p>Dose modifications (dose delays or dose reductions) due to adverse reactions occurred in 74% of the patients. The most common adverse reactions (≥5%) that led to dose modifications include <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (30%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (13%), lipase increased (12%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (11%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (11%), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (6%), and ALT, AST, or <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">GGT increased</span> (6%).</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5: Adverse  Reactions Occurring in &gt;10% of Patients, Any Group</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">CP-CML<br>(N=270)</th>
<th class="Rrule" align="center" colspan="2">AP-CML<br>(N=85)</th>
<th class="Rrule" align="center" colspan="2">BP-CML<br>(N=62)</th>
<th class="Rrule" align="center" colspan="2">Ph+ ALL<br>(N=32)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">System Organ Class</th>
<th class="Rrule" align="center">Any Grade<br>(%)</th>
<th class="Rrule" align="center">CTCAE Grade<br>3 / 4<br>(%)</th>
<th class="Rrule" align="center">Any Grade<br>(%)</th>
<th class="Rrule" align="center">CTCAE Grade<br>3 / 4<br>(%)</th>
<th class="Rrule" align="center">Any Grade<br>(%)</th>
<th class="Rrule" align="center">CTCAE Grade<br>3 / 4<br>(%)</th>
<th class="Rrule" align="center">Any Grade<br>(%)</th>
<th class="Rrule" align="center">CTCAE Grade<br>3 / 4<br>(%)</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="9">Adverse drug reactions, reported using MedDRA and graded using NCI-CTC-AE v 4.0 (NCI Common Terminology Criteria for Adverse Events) for assessment of toxicity.</td></tr>
<tr class="Last"><td align="left" colspan="9">Treatment-emergent, all causality events</td></tr>
<tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>derived from blood pressure (BP) measurement recorded monthly while on trial</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>includes cardiovascular, cerebrovascular, and peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span></dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>represents an additional 13 months of follow-up </dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">cardiac failure congestive</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, <span class="product-label-link" type="condition" conceptid="4259490" conceptname="Cardiorespiratory failure">cardiopulmonary failure</span>, <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> decreased, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4273632" conceptname="Right ventricular failure">right ventricular failure</span></dd>
<dt><a name="footnote-8" href="#footnote-reference-8">¶</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span></dd>
<dt><a name="footnote-9" href="#footnote-reference-9">#</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, lip <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, oral mucosal <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pharyngeal ulceration, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4278836" conceptname="Ulcer on tongue">tongue ulceration</span></dd>
<dt><a name="footnote-10" href="#footnote-reference-10">Þ</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4231580" conceptname="Acute gastric ulcer with hemorrhage">gastric ulcer hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="195309" conceptname="Eosinophilic gastritis">hemorrhagic gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="4198840" conceptname="Bleeding hemorrhoids">hemorrhoidal hemorrhage</span>, intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4291649" conceptname="Upper gastrointestinal hemorrhage">upper gastrointestinal hemorrhage</span></dd>
<dt><a name="footnote-11" href="#footnote-reference-11">ß</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, peripheral sensorimotor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4319472" conceptname="Peripheral motor neuropathy">peripheral motor neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">peripheral sensory neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span></dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Cardiac or <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">68</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">71</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">65</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">31</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Arterial <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> <a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a><a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> <a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a><a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> <a name="footnote-reference-8" href="#footnote-8" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Oral <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> <a name="footnote-reference-9" href="#footnote-9" class="Sup">#</a>
</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span> <a name="footnote-reference-10" href="#footnote-10" class="Sup">Þ</a>
</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Blood and lymphatic system disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">22</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> <a name="footnote-reference-11" href="#footnote-11" class="Sup">ß</a><a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and related conditions</td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, peripheral</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Investigations</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="80%">
<caption><span>Table 6: Serious Adverse Reactions (SAR)</span></caption>
<col align="left" valign="top" width="75%">
<col align="center" valign="top" width="25%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N (%)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>represents an additional 13 months of follow-up </dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Arterial ischemic event<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">53 (11.8%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Cardiovascular</td>
<td class="Rrule" align="center">28 (6.2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Cerebrovascular</td>
<td class="Rrule" align="center">18 (4.0%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Peripheral vascular</td>
<td class="Rrule" align="center">16 (3.6%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td class="Rrule" align="center">22 (4.9%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    CNS <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></td>
<td class="Rrule" align="center">10 (2.2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span></td>
<td class="Rrule" align="center">10 (2.2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span><a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">22 (4.9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">Effusions</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center">13 (2.9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span></td>
<td class="Rrule" align="center">11 (2.4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span></td>
<td class="Rrule" align="center">10 (2.2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">8 (1.8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></td>
<td class="Rrule" align="center">23 (5.1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">17 (3.8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Blood and lymphatic system disorders</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td class="Rrule" align="center">13 (2.9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">13 (2.9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">12 (2.7%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">24 (5.3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></td>
<td class="Rrule" align="center">11 (2.4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">14 (3.1%)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Laboratory Abnormalities</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> was commonly reported in all patient populations. The frequency of grade 3 or 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was higher in patients with AP-CML, BP-CML, and Ph+ ALL than in patients with CP-CML (see <a href="#table7">Table 7</a>).</p>
<a name="table7"></a><table width="80%">
<caption><span>Table 7: Incidence of Clinically Relevant Grade 3/4<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> Hematologic Abnormalities</span></caption>
<col align="left" valign="middle" width="36%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="center">Laboratory Test</th>
<th class="Rrule" align="center">CP-CML<br>(N=270)<br>(%)</th>
<th class="Rrule" align="center">AP-CML<br>(N=85)<br>(%)</th>
<th class="Rrule" align="center">BP-CML<br>(N=62)<br>(%)</th>
<th class="Rrule" align="center">Ph+ ALL<br>(N=32)<br>(%)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">ANC=absolute neutrophil count, Hgb=hemoglobin, WBC=white blood cell count</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Reported using NCI-CTC-AE v 4.0</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Hematology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (platelet count decreased)</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">47</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (ANC decreased)</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">63</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (WBC decreased)</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">63</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb decreased)</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">34</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">22</td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="80%">
<caption><span>Table 8: Incidence of Clinically Relevant Non-Hematologic Laboratory Abnormalities</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2" valign="middle">Laboratory Test</th>
<th class="Rrule" align="center" colspan="2">Safety Population<br>N=449</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Any Grade<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a><br>(%)</th>
<th class="Rrule" align="center">CTCAE Grade 3/4<br>(%)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">ALT=<span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>, AST=<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Graded using NCI-CTC-AE v 4.0</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Liver function tests</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ALT increased</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  AST increased</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Alkaline phosphatase increased</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Albumin decreased</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Bilirubin increased</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Pancreatic enzymes</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Lipase increased</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Amylase increased</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Chemistry</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Glucose increased</td>
<td class="Rrule" align="center">58</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Phosphorus decreased</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Calcium decreased</td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Sodium decreased</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Glucose decreased</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Potassium decreased</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Potassium increased</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Sodium increased</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> decreased</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Creatinine increased</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Calcium increased</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  Triglycerides increased</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">Based on <span class="Italics">in vitro</span> studies, ponatinib is a substrate of CYP3A and to a lesser extent CYP2C8 and CYP2D6. Ponatinib also inhibits the P-glycoprotein (P-gp), ATP-binding cassette G2 (ABCG2) [also known as BCRP], and bile salt export pump (BSEP) transporter systems <span class="Italics">in vitro </span><span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Drugs That Are Strong Inhibitors of CYP3A Enzymes</h2>
<p class="First">In a drug interaction study in healthy volunteers, co-administration of Iclusig with ketoconazole increased plasma ponatinib AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span> by 78% and 47%, respectively <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. When administering Iclusig with strong CYP3A inhibitors (e.g., boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole), the recommended starting dose should be reduced <span class="Italics"> [see<a href="#S2.4"> Dosage and Administration (2.4)</a>]</span>. Patients taking concomitant strong CYP3A inhibitors may be at increased risk for adverse reactions <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Drugs That Are Strong Inducers of CYP3A Enzymes</h2>
<p class="First">Coadministration of strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, and St. John's Wort) with Iclusig should be avoided unless the benefit outweighs the risk of decreased ponatinib exposure.  Monitor patients for reduced efficacy. Selection of concomitant medication with no or minimal CYP3A induction potential is recommended. In a drug interaction study in healthy volunteers, co-administration of Iclusig following multiple doses of rifampin resulted in decreased ponatinib AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span> values by 62% and 42%, respectively  <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Drugs That Elevate Gastric pH</h2>
<p class="First">Iclusig may be co-administered with gastric pH-elevating medications. In a drug interaction study in healthy volunteers, co-administration of Iclusig following multiple doses of lansoprazole resulted in a minimal (6%) decrease in ponatinib exposure. <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4		Drugs That Are Substrates of the P-gp or ABCG2 Transporter Systems</h2>
<p class="First"><span class="Italics">In vitro</span> studies demonstrate that Iclusig inhibits the P-gp and ABCG2 transporter systems. The effect of coadministration of Iclusig with sensitive substrates of the P-gp (e.g., aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, tolvaptan, topotecan) and ABCG2 (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) transporter systems on exposure of these substrates has not been evaluated in clinical studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>Based on its mechanism of action and findings in animals, Iclusig can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies with Iclusig in pregnant women. Advise women to avoid becoming pregnant while taking Iclusig. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Ponatinib was studied for effects on embryo-fetal development in pregnant rats given oral doses of 0.3, 1, and 3 mg/kg/day during organogenesis. At the maternally toxic dose of 3 mg/kg/day (equivalent to the AUC in patients receiving the recommended dose of 45 mg/day), ponatinib caused embryo-fetal toxicity as shown by increased resorptions, reduced body weight, external alterations, multiple soft tissue and skeletal alterations, and reduced ossification. Embryo-fetal toxicities also were observed at 1 mg/kg/day (approximately 24% the AUC in patients receiving the recommended dose) and involved multiple fetal soft tissue and skeletal alterations, including reduced ossification.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is unknown whether ponatinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ponatinib, a decision should be made whether to discontinue nursing or to discontinue Iclusig, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The safety and efficacy of Iclusig in patients less than 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">One hundred and fifty-five of 449 patients (35%) in the clinical trial of Iclusig were 65 years of age and over. In patients with CP-CML, patients of age ≥ 65 years had a lower major cytogenetic response rate (38%) as compared with patients &lt; 65 years of age (64%). In patients with AP-CML, BP-CML, and Ph+ ALL, patients of age ≥ 65 years had a higher major hematologic response rate (47%) as compared with patients &lt; 65 years of age (40%). Forty-six percent of patients ≥ 65 years had <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> events. Patients of age ≥ 65 years are more likely to experience adverse reactions including <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> decreased platelet count, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, increased lipase, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Administer Iclusig at a dose of 30 mg once daily in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A, B, or C). [<span class="Italics">see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>In a single-dose (30 mg) pharmacokinetic (PK) study; compared to subjects with normal liver function, no major differences in ponatinib PK were observed in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A, B, or C)<span class="Italics">.</span>  However, there was an increased overall incidence of adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, including a case of severe <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) in the subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> following the single 30 mg dose compared to subjects with normal liver function. The safety of multiple ponatinib doses, or doses higher than 30 mg have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Iclusig has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Although renal excretion is not a major route of ponatinib elimination, the potential for moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> to affect hepatic elimination has not been determined <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> with Iclusig were reported in clinical trials. One patient was accidentally administered the entire contents of a bottle of study medication via nasogastric tube. The investigator estimated that the patient received 540 mg of Iclusig. Two hours after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient had an uncorrected QT interval of 520 ms. Subsequent ECGs showed normal sinus rhythm with uncorrected QT intervals of 480 and 400 ms. The patient died 9 days after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> from <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Another patient accidentally self-administered 165 mg on cycle 1 day 2. The patient experienced <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4164649" conceptname="Non-cardiac chest pain">non-cardiac chest pain</span> on day 3. Multiple doses of 90 mg per day for 12 days in a patient resulted in <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic inflammatory response, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, and a moderate <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Iclusig, stop Iclusig, observe the patient and provide appropriate supportive treatment.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Iclusig (ponatinib) is a kinase inhibitor. The chemical name for ponatinib hydrochloride is 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide hydrochloride. The molecular formula is C<span class="Sub">29</span>H<span class="Sub">28</span>ClF<span class="Sub">3</span>N<span class="Sub">6</span>O which corresponds to a formula weight of 569.02 g/mol. Its structure is shown below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=807f988e-117b-4497-934d-73aa78baac71&amp;name=iclusig-01.jpg"></div>
<p>Ponatinib HCl is an off-white to yellow powder with pKa of 2.77 and 7.8. The solubility of ponatinib in pH 1.7, 2.7, and 7.5 buffers is 7790 mcg/ml, 3.44 mcg/ml, and 0.16 mcg/ml, respectively, indicating a decrease in solubility with increasing pH. Iclusig tablets are available as white, round, film-coated tablets for oral administration. Each tablet contains ponatinib hydrochloride equivalent to 15 or 45 mg ponatinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type B), colloidal silicon dioxide, magnesium stearate and a tablet coating. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 	Mechanism of Action</h2>
<p class="First">Ponatinib is a kinase inhibitor. Ponatinib inhibited the <span class="Italics">in vitro</span> tyrosine kinase activity of ABL and T315I mutant ABL with IC<span class="Sub">50</span> concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the <span class="Italics">in vitro</span> activity of additional kinases with IC<span class="Sub">50</span> concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the <span class="Italics">in vitro</span> viability of cells expressing native or mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR-ABL when compared to controls.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 	Pharmacodynamics</h2>
<p class="First">In a cell-based assay, ponatinib concentrations of 20 nM (10.65 ng/mL) were sufficient to suppress most BCR-ABL mutant clones. However, ponatinib concentrations of 40 nM (21.3 ng/mL) were required to suppress T315I mutants.  The median and range of steady-state C<span class="Sub">max</span> and trough (C<span class="Sub">min</span>) concentrations of ponatinib following 29 days of once-daily dosing of 15 mg, 30 mg and 45 mg are listed in Table 9.</p>
<a name="table9"></a><table width="75%">
<caption><span>Table 9: Median, Maximum, and Minimum Ponatinib Exposure at Steady-State by Dose Group:  PK Evaluable Population</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dose</th>
<th class="Rrule" align="center">Median C<span class="Sub">max</span> (Range)<br>(nM)</th>
<th class="Rrule" align="center">Median C<span class="Sub">min</span> (Range)<br>(nM)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">15 mg QD (n = 8)</td>
<td class="Rrule" align="center">49 (23 – 105)</td>
<td class="Rrule" align="center">28 (11 – 68)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">30 mg QD (n = 9)</td>
<td class="Rrule" align="center">125 (67 – 178)</td>
<td class="Rrule" align="center">		54 (41 – 89)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">45 mg QD (n = 21)</td>
<td class="Rrule" align="center">161 (64 – 336)</td>
<td class="Rrzzz" align="center">67 (22 – 137)</td>
</tr>
</tbody>
</table>
<p>Concentrations of ponatinib shown in cell-based assays to suppress unmutated BCR-ABL and most mutant BCR-ABL clones may be achieved at once daily dosing of 15 mg or 30 mg.  </p>
<p>The dose intensity-safety relationship indicated that there are significant increases in grade ≥ 3 adverse events (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, ALT increase, AST increase, lipase increase, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>) over the dose range of 15 to 45 mg once-daily.</p>
<p>In vitro, there was no significant inhibition of platelet aggregation with ponatinib at concentrations seen clinically and up to 0.7 μg/mL (1.23 μM).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Cardiac Electrophysiology</span></p>
<p>A QT assessment was performed in 39 patients with cancer who received 30 mg, 45 mg, or 60 mg Iclusig once daily.  No large changes in the mean QTc interval (i.e., &gt; 20 ms) from baseline were detected in the study.  However, a small increase in the mean QTc interval (i.e., &lt; 10 ms) cannot be excluded because of study design limitations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">The geometric mean (CV%) C<span class="Sub">max</span> and AUC(<span class="Sub">0-τ</span>) of Iclusig 45 mg daily at presumed steady state in patients with advanced hematologic malignancies were 73 ng/mL (74%) and 1253 ng•hr/mL (73%), respectively. Ponatinib administered as an investigational capsule formulation to patients with cancer exhibited approximately dose proportional increases in both C<span class="Sub">max</span> and AUC over the dose range of 15 to 60 mg.  A dose intensity safety analysis showed a significant increase in grade 3 or higher adverse reactions (i.e., <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, ALT elevation, AST elevation, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and lipase elevation) with an increase in dose intensity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>The absolute bioavailability of ponatinib is unknown. Peak concentrations of ponatinib are observed within 6 hours after Iclusig oral administration. Following ingestion of either a high-fat or low-fat meal by 22 healthy volunteers, plasma ponatinib exposures (AUC and C<span class="Sub">max</span>) were not different when compared to fasting conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Ponatinib is greater than 99% bound to plasma proteins <span class="Italics">in vitro</span>. There was no plasma protein binding displacement of ponatinib (145 nM) <span class="Italics">in vitro</span> by other highly protein bound medications (ibuprofen, nifedipine, propranolol, salicylic acid, and warfarin).  The geometric mean (CV%) apparent steady state volume of distribution is 1223 liters (102%) following oral administration of Iclusig 45 mg once daily for 28 days in patients with cancer. Ponatinib is a weak substrate for both P-gp and ABCG2 <span class="Italics">in vitro</span>. Ponatinib is not a substrate for organic anion transporting polypeptides (OATP1B1, OATP1B3) and organic cation transporter 1 (OCT1) <span class="Italics">in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>At least 64% of a ponatinib dose undergoes phase I and phase II metabolism. CYP3A4 and to a lesser extent CYP2C8, CYP2D6 and CYP3A5 are involved in the phase I metabolism of ponatinib <span class="Italics">in vitro. </span>Ponatinib is also metabolized by esterases and/or amidases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>The geometric mean (range) terminal elimination half-life of ponatinib was approximately 24 (12 to 66) hours following Iclusig 45 mg oral administration once daily for 28 days in patients with cancer. Exposure increased by approximately 90% (median) [range: 20% to 440%] between the first dose and presumed steady state. Ponatinib is mainly eliminated via feces. Following a single oral dose of [<span class="Sup">14</span>C]-labeled ponatinib, approximately 87% of the radioactive dose is recovered in the feces and approximately 5% in the urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Underline">Coadministration of Ponatinib and CYP3A Inhibitors</span></p>
<p>Coadministration of a single 15 mg oral dose of ponatinib in the presence of ketoconazole (400 mg daily), a strong CYP3A inhibitor, to 22 healthy volunteers, increased the AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span> of ponatinib by 78% and 47%, respectively, when compared to administration of ponatinib alone <span class="Italics">[see<a href="#S7.1"> Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Underline">Coadministration of Ponatinib and CYP3A Inducers</span></p>
<p>Co-administration of a single 45 mg dose of ponatinib in the presence of rifampin (600 mg daily), a strong CYP3A inducer, to 19 healthy volunteers, decreased the AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span> of ponatinib by 62% and 42%, respectively, when compared to administration of ponatinib alone <span class="Italics"><a href="#S7.2">[see Drug Interactions (7.2)]</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Underline">Coadministration With Other CYP Substrates</span></p>
<p><span class="Italics">In vitro</span> studies indicate that ponatinib does not inhibit the metabolism of substrates for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A, or CYP2D6 and does not induce the metabolism of substrates for CYP1A2, CYP2B6, or CYP3A.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Underline">Coadministration With Substrates of Transporters</span></p>
<p><span class="Italics">In vitro</span>, ponatinib is an inhibitor of P-gp and ABCG2, and BSEP <span class="Italics">[see<a href="#S7.4"> Drug Interactions (7.4)</a>]</span>.</p>
<p><span class="Italics">In vitro</span>, ponatinib did not inhibit the human organic anion transporting polypeptides OATP1B1 or OATP1B3, or the organic cation transporters OCT1, OCT2, OAT1, and OAT3.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Underline">Coadministration of Ponatinib and Gastric pH elevating Medications</span></p>
<p>The aqueous solubility of ponatinib is pH dependent, with higher pH resulting in lower solubility <span class="Italics">[see <a href="#S11">Description (11)</a>]</span>. Co-administration of a single 45 mg dose of ponatinib in the presence of lansoprazole (60 mg daily), a proton pump inhibitor, to 18 healthy volunteers decreased the AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span> of ponatinib by 6% and 25%, respectively, when compared to administration of ponatinib alone <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics in Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>A single 30 mg oral dose of ponatinib was administered to subjects with normal liver function (N=8) and to subjects with mild [Child-Pugh A (N=6)], moderate [Child-Pugh B (N=6)], and severe [Child-Pugh C (N=4)] <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Compared to subjects with normal liver function,  there was no trend of increased ponatinib exposure in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. There was an increased incidence of adverse reactions in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to subjects with normal liver function <span class="Italics"><a href="#S2.5">[see Dosage and Administration (2.5)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Iclusig has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Although renal excretion is not a major route of ponatinib elimination, the potential for moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> to affect hepatic elimination has not been determined <span class="Italics">[see<a href="#S8.7"> Use in Specific Populations (8.7)</a>].</span></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been performed with ponatinib.</p>
<p>Ponatinib was not mutagenic in a bacterial mutagenesis (Ames) assay, was not clastogenic in a chromosome aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, nor was it clastogenic in an <span class="Italics">in vivo</span> mouse micronucleus assay at oral doses up to 2000 mg/kg.</p>
<p>Ponatinib may impair male and female fertility. Fertility studies using ponatinib were not conducted. However, ponatinib effects on male and female reproductive organs observed during general toxicology studies included degeneration of epithelium of the testes in rats and monkeys and follicular atresia in the monkey ovary with associated endometrial <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. Effects seen in rats were at exposures approximating the AUC in patients receiving the recommended dose of 45 mg/day and in monkeys were approximately 4 times the AUC in patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 	CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of Iclusig in patients with CML and Ph+ ALL whose disease was considered to be resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy were evaluated in a single-arm, open-label, international, multicenter trial. Efficacy results described below should be interpreted within the context of updated safety information<span class="Italics"> [see<a href="#BOX"> Boxed Warning</a>,<a href="#S2.1"> Dosage and Administration (2.1)</a>, and<a href="#S5.1"> Warnings and Precautions (5.1</a>,<a href="#S5.2"> 5.2)</a>]</span></p>
<p>All patients were administered a starting dose of 45 mg of Iclusig once daily. Patients were assigned to one of six cohorts based on disease phase (chronic phase CML [CP-CML]; accelerated phase CML [AP-CML]; or blast phase CML /Philadelphia-positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> [BP-CML/Ph+ ALL]), resistance or intolerance (R/I) to prior TKI therapy, and the presence of the T315I mutation.</p>
<p>Resistance in CP-CML while on prior TKI therapy, was defined as failure to achieve either a complete hematologic response (by 3 months), a minor cytogenetic response (by 6 months), or a major cytogenetic response (by 12 months). Patients with CP-CML who experienced a loss of response or development of a kinase domain mutation in the absence of a complete cytogenetic response or progression to AP-CML or BP-CML at any time on prior TKI therapy were also considered resistant. Resistance in AP-CML, BP-CML, and Ph+ ALL was defined as failure to achieve either a major hematologic response (by 3 months in AP-CML, and by 1 month in BP-CML and Ph+ ALL), loss of major hematologic response (at any time), or development of a kinase domain mutation in the absence of a complete major hematologic response while on prior TKI therapy.</p>
<p>Intolerance was defined as the discontinuation of prior TKI therapy due to toxicities despite optimal management in the absence of a complete cytogenetic response in patients with CP-CML or major hematologic response for patients with AP-CML, BP-CML, or Ph+ ALL.</p>
<p>The primary efficacy endpoint in CP-CML was major cytogenetic response (MCyR), which included complete and partial cytogenetic responses (CCyR and PCyR). The primary efficacy endpoint in AP-CML, BP-CML, and Ph+ ALL was major hematologic response (MaHR), defined as either a complete hematologic response (CHR) or no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (NEL).</p>
<p>The trial enrolled 449 patients, of which 444 were eligible for efficacy analysis: 267 patients with CP-CML (R/I Cohort: n=203, T315I: n=64), 83 patients with AP-CML, 62 patients with BP-CML, and 32 patients with Ph+ ALL. Five patients were not eligible for efficacy analysis due to lack of confirmation of T315I mutation status, and these patients had not received prior dasatinib or nilotinib.</p>
<p>At the time of analysis, the median follow-up was 10 months (minimum of 6 months of follow-up for all ongoing patients). Baseline demographic characteristics are described in Table 10.</p>
<a name="table10"></a><table width="80%">
<caption><span>Table 10: Demographic and Disease Characteristics</span></caption>
<col align="left" valign="top" width="70%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" valign="middle">Patient Characteristics at Entry</th>
<th class="Rrule" align="center">Efficacy Population<br>N=444</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Of the patients with one or more BCR-ABL kinase domain mutations detected at entry, 37 unique mutations were detected.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Age</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median, years (range)</td>
<td class="Rrule" align="center">59 (18 to 94)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Gender, n (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Male</td>
<td class="Rrule" align="center">236 (53%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Race, n (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Asian</td>
<td class="Rrule" align="center">57 (13%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Black or African American</td>
<td class="Rrule" align="center">25 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  White</td>
<td class="Rrule" align="center">349 (79%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Other</td>
<td class="Rrule" align="center">13 (3%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">ECOG Performance Status, n (%)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ECOG=0 or 1</td>
<td class="Rrule" align="center">409 (92%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Disease History</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median time from diagnosis to first dose, years (range)</td>
<td class="Rrule" align="center">6.1 (0.3 to 28.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Resistant to Prior TKI Therapy, n (%)</td>
<td class="Rrule" align="center">374 (88%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Presence of one or more BCR-ABL kinase domain mutations<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</td>
<td class="Rrule" align="center">244 (55%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Prior TKI therapy– number of prior approved TKIs, n (%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">      1</td>
<td class="Rrule" align="center">29 (7%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">      2</td>
<td class="Rrule" align="center">166 (37%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    ≥3</td>
<td class="Rrule" align="center">249 (56%)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
<p>At the time of analysis, the median duration of Iclusig treatment was 281 days in patients with CP-CML, 286 days in patients with AP-CML, 89 days in patients with BP-CML, and 81 days in patients with Ph+ ALL. Efficacy results are summarized in Table 11, and Table 12.</p>
<a name="table11"></a><table width="80%">
<caption><span>Table 11: Efficacy of Iclusig in Patients With Resistant or Intolerant Chronic Phase CML</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Rrule" align="center" rowspan="2" valign="middle">Overall<br>(N=267)</th>
<th class="Rrule" align="center" colspan="2">Cohort</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center">R/I<br>Cohort<br>(N=203)</th>
<th class="Rrule" align="center">T315I<br>Cohort<br>(N=64)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Cytogenetic Response</th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>Primary endpoint for CP-CML Cohorts was MCyR, which combines both complete (no detectable Ph+ cells) and partial (1% to 35% Ph+ cells in at least 20 metaphases) cytogenetic responses.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">  Major <a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a> (MCyR)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  %</td>
<td class="Rrule" align="center">54%</td>
<td class="Rrule" align="center">49%</td>
<td class="Rrule" align="center">70%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  (95% CI)</td>
<td class="Rrule" align="center">(48,60)</td>
<td class="Rrule" align="center">(42,56)</td>
<td class="Rrule" align="center">(58,81)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Complete (CCyR)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    %</td>
<td class="Rrule" align="center">44%</td>
<td class="Rrule" align="center">37%</td>
<td class="Rrule" align="center">66%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">    (95% CI)</td>
<td class="Rrule" align="center">(38,50)</td>
<td class="Rrule" align="center">(31,44)</td>
<td class="Rrule" align="center">(53,77)</td>
</tr>
</tbody>
</table>
<p>In patients with CP-CML patients who achieved MCyR, the median time to MCyR was 84 days (range: 49 to 334 days). At the time of analysis, the median durations of MCyR had not yet been reached.</p>
<a name="table12"></a><table width="80%">
<caption><span>Table 12: Efficacy of Iclusig in Patients With Resistant or Intolerant Advanced Disease (includes R/I and T315I cohorts)</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">AP-CML<br>Overall<br>(N=83)</th>
<th class="Rrule" align="center">BP-CML<br>Overall<br>(N=62)</th>
<th class="Rrule" align="center">Ph+ ALL<br>Overall<br>(N=32)</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left">Hematologic Response</th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Primary endpoint for patients with AP-CML, BP-CML, and Ph+ ALL was MaHR, which combines complete hematologic responses and no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>CHR: WBC ≤ institutional ULN, ANC ≥1000/mm<span class="Sup">3</span>, platelets ≥100,000/mm<span class="Sup">3</span>, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤5%, &lt;5% myelocytes plus metamyelocytes in peripheral blood, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span> &lt;5% in peripheral blood, No extramedullary involvement (including no <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> or <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">  Major<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a> (MaHR)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  %</td>
<td class="Rrule" align="center">52%</td>
<td class="Rrule" align="center">31%</td>
<td class="Rrule" align="center">41%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  (95% CI)</td>
<td class="Rrule" align="center">(41,63)</td>
<td class="Rrule" align="center">(20,44)</td>
<td class="Rrule" align="center">(24,59)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Complete<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a> (CHR)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    %</td>
<td class="Rrule" align="center">47%</td>
<td class="Rrule" align="center">21%</td>
<td class="Rrule" align="center">34%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">    (95% CI)</td>
<td class="Rrule" align="center">(33,55)</td>
<td class="Rrule" align="center">(12,33)</td>
<td class="Rrule" align="center">(19,53)</td>
</tr>
</tbody>
</table>
<p>The median time to MaHR in patients with AP-CML, BP-CML, and Ph+ ALL was 21 days (range: 12 to 176 days), 29 days (range 12 to 113 days), and 20 days (range: 11 to 168 days), respectively. The median duration of MaHR for patients with AP-CML, BP-CML, and Ph+ ALL was 9.5 months (range: 1.1 to 17.7 months), 4.7 months (range: 1.8 to 14.1+ months), and 3.2 months (range: 1.8 to 8.8+ months), respectively.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Iclusig tablets are available in the following configurations:</p>
<table width="80%">
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Strength</th>
<th class="Rrule" align="center">NDC Number</th>
<th class="Rrule" align="center">Description</th>
<th class="Rrule" align="center">Presentation</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="3">15 mg</td>
<td class="Rrule" align="center">76189-535-30</td>
<td class="Rrule" align="left" rowspan="3">round, white, film-coated tablets with debossed "A5" on one side and plain on the other side</td>
<td class="Rrule" align="left">30 tablets in a wide-mouth white high density polyethylene (HDPE) bottle with child resistant closures that incorporate an induction heat seal liner</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">76189-535-60</td>
<td class="Rrule" align="left">60 tablets in a wide-mouth white high density polyethylene (HDPE) bottle with child resistant closures that incorporate an induction heat seal liner</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">76189-535-80</td>
<td class="Rrule" align="left">180 tablets in a wide-mouth white high density polyethylene (HDPE) bottle with child resistant closures that incorporate an induction heat seal liner</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">45 mg</td>
<td class="Rrule" align="center">76189-534-30</td>
<td class="Rrule" align="left" rowspan="2">round, white, film-coated tablets with debossed "AP4" on one side and plain on the other side</td>
<td class="Rrule" align="left">30 tablets in a wide-mouth white high density polyethylene (HDPE) bottle with child resistant closures that incorporate an induction heat seal liner</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">76189-534-90</td>
<td class="Rrule" align="left">90 tablets in a wide-mouth white high density polyethylene (HDPE) bottle with child resistant closures that incorporate an induction heat seal liner</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Iclusig tablets should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature]. Keep away from children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 	PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#MED">FDA-Approved Patient Labeling (Medication Guide)</a>.</p>
<p><span class="Bold">Advise patients of the following and provide a copy of the Medication Guide: </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">Vascular Occlusions</span></span></p>
<p>Inform patients that serious arterial thromboses (including arterial stenosis sometimes requiring revascularization) and <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> events have occurred. Advise patients to immediately contact their health care provider with any symptoms suggestive of a blood clot such as <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body, speech problems, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, or leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span></span></p>
<p>Inform patients of the possibility of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and abnormally slow or fast heart rates. Advise patients to contact their health care provider if they experience symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span><span class="Italics"> [see<a href="#S5.2"> Warnings and Precautions (5.2</a>,<a href="#S5.10"> 5.10)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Underline">Hepatotoxicity</span></p>
<p>Inform patients of the possibility of developing liver function abnormalities and serious hepatic toxicity. Advise patients to immediately contact their health care provider if signs of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> occur, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>  <span class="Italics">[see<a href="#S5.3"> Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>Inform patients of the possibility of new or worsening of existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Advise patients to contact their health care provider for elevated blood pressure or if symptoms of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> occur including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span></p>
<p>Inform patients of the possibility of developing <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> that may be accompanied by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and to promptly report these symptoms <span class="Italics">[see<a href="#S5.5"> Warnings and Precautions (5.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.6"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></span></p>
<p>Inform patients of the possibility of developing peripheral or <span class="product-label-link" type="condition" conceptid="441848" conceptname="Cranial nerve disorder">cranial neuropathy</span> while being treated with Iclusig. Advise patients to report symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, such as <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, a <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span><span class="Italics"> [see<a href="#S5.6"> Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.7"></a><p></p>
<p class="First"><span class="Underline">Ocular Toxicity</span></p>
<p>Inform patients of the possibility of ocular toxicity while being treated with Iclusig. Advise patients to report symptoms of ocular toxicity, such as <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span><span class="Italics"> [see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.8"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></p>
<p>Inform patients of the possibility of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and to immediately contact their health care provider with any signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> such as unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span><span class="Italics"> [see<a href="#S5.8"> Warnings and Precautions (5.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.9"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></p>
<p>Inform patients of the possibility of developing <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and to contact their health care provider for symptoms such as leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, abdominal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> <span class="Italics">[see<a href="#S5.9"> Warnings and Precautions (5.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.10"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></span></p>
<p>Inform patients of the possibility of developing low blood cell counts; inform patients to report immediately should <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> develop, particularly in association with any suggestion of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see<a href="#S5.11"> Warnings and Precautions (5.11)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.11"></a><p></p>
<p class="First"><span class="Underline">Compromised <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing and <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></span></p>
<p>Advise patients to inform their health care provider if they plan to undergo a surgical procedure or had recent surgery <span class="Italics">[see<a href="#S5.13"> Warnings and Precautions (5.13)</a>]</span>.</p>
<p>Inform patients that cases of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> have been reported <span class="Italics">[see<a href="#S5.13"> Warnings and Precautions (5.13)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.12"></a><p></p>
<p class="First"><span class="Underline">Embryo-Fetal Toxicity</span></p>
<p>Inform patients that Iclusig can cause fetal harm when administered to a pregnant woman. Advise women of the potential hazard to a fetus and to avoid becoming pregnant <span class="Italics">[see<a href="#S5.14"> Warnings and Precautions (5.14) </a>and<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.13"></a><p></p>
<p class="First"><span class="Underline">Instructions for Taking Iclusig</span></p>
<p>Advise patients to take Iclusig exactly as prescribed and not to change their dose or to stop taking Iclusig unless they are told to do so by their health care provider. Iclusig may be taken with or without food. Iclusig tablets should be swallowed whole. Patients should not crush or dissolve the tablets.</p>
<p>Patients should not take two doses at the same time to make up for a missed dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.14"></a><p></p>
<p class="First"><span class="Underline">Lactose</span></p>
<p>Inform patients that Iclusig contains 121 mg of lactose monohydrate in a 45 mg daily dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for:<br>ARIAD Pharmaceuticals, Inc.<br>26 Landsdowne Street<br>Cambridge, MA 02139-4234</p>
<p>AIL150 Rev 0, ######_###_#</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MED"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>Iclusig<span class="Sup">®</span> (eye-CLUE-sig)<br>(ponatinib)<br>Tablets</span></p>
<p><a name="MI"></a><span class="Bold">What is the most important information I should know about Iclusig?</span></p>
<p><span class="Bold">Iclusig can cause serious side effects, including:</span></p>
<p><span class="Bold">Blood clots or blockage in your blood vessels (arteries and veins). </span>Blood clots or blockage in your blood vessels may lead to <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. A blood clot or blockage in your blood vessels can prevent proper blood flow to your heart, brain, bowels (intestines), legs, eyes, and other parts of your body. You may need emergency surgery or treatment in a hospital. Get medical help right away if you get any of the following symptoms:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or pressure</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms, legs, back, neck or jaw</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of your body</li>
<li>trouble talking</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>severe stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </li>
<li>decreased vision or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> </li>
</ul>
<p>Blood clots or blockage in your blood vessels can happen in people with or without risk factors for heart and blood vessel disease, including people 50 years of age or younger. Talk to your healthcare provider if this is a concern for you.</p>
<p><span class="Bold">Heart problems.  </span>Iclusig can cause heart problems, including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> which can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood well enough. Iclusig can also cause irregular slow or fast heartbeats and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Your healthcare provider will check your heart function before and during your treatment with Iclusig. Get medical help right away if you get any of the following symptoms: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, fast or irregular heartbeats, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>.</p>
<p><span class="Bold">Liver problems.</span>  Iclusig can cause liver problems, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, which can be severe and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your healthcare provider will do blood tests before and during your treatment with Iclusig to check for liver problems. Get medical help right away if you get any of these symptoms of liver problems during treatment:</p>
<ul class="Disc">
<li>yellowing of your skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark "tea-colored" urine</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li>
</ul>
<p>See<span class="Bold"> "<a href="#sidefx">What are the possible side effects of Iclusig</a>?" </span>for information about side effects.</p>
<p><span class="Bold">What is Iclusig?</span></p>
<p>Iclusig is a prescription medicine used to treat adults who have: </p>
<ul class="Disc">
<li>a specific type of abnormal gene (T315I-positive) chronic phase, accelerated phase, or blast phase <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML), T315I-positive Philadelphia chromosome positive <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (Ph + ALL)</li>
<li>chronic phase, accelerated phase, or blast phase CML or Ph+ ALL who cannot receive any other tyrosine kinase inhibitor (TKI) medicines</li>
</ul>
<p>It is not known if Iclusig is safe and effective in children less than 18 years of age.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking Iclusig?</span></p>
<p><span class="Bold">Before you take Iclusig, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have a history of blood clots in your blood vessels (arteries or veins)</li>
<li>have heart problems, including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, irregular heartbeats, and QT prolongation</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </li>
<li>have a history of high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>have liver problems</li>
<li>have had <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</li>
<li>have high blood pressure</li>
<li>have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>plan to have any surgical procedures</li>
<li>are lactose (milk sugar) intolerant. Iclusig tablets contain lactose.</li>
<li>drink grapefruit juice </li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. Iclusig can harm your unborn baby. You should not become pregnant while taking Iclusig. Tell your healthcare provider right away if you become pregnant or plan to become pregnant.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if Iclusig passes into your breast milk. You and your healthcare provider should decide if you will take Iclusig or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements.  Iclusig and other medicines may affect each other causing side effects.</p>
<p>Know the medicines you take.  Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Iclusig?</span></p>
<ul>
<li>Take Iclusig exactly as your healthcare provider tells you to take it.</li>
<li>Your healthcare provider may change your dose of Iclusig or tell you to stop taking Iclusig.</li>
<li>Do not change your dose or stop taking Iclusig without talking to your healthcare provider.</li>
<li>Swallow Iclusig tablets whole.  Do not crush or dissolve Iclusig tablets.</li>
<li>You may take Iclusig with or without food. </li>
<li>If you miss a dose of Iclusig, take your next dose at your regular time.  Do not take 2 doses at the same time to make up for a missed dose. </li>
<li>If you take too much Iclusig, call your healthcare provider or go to the nearest hospital emergency room right away.</li>
</ul>
<p><a name="sidefx"></a><span class="Bold">What are the possible side effects of Iclusig?</span></p>
<p><span class="Bold">Iclusig may cause serious side effects, including:</span></p>
<ul class="Disc">
<li>See <span class="Bold">"<a href="#MI">What is the most important information I should know about Iclusig?</a>"</span>
</li>
<li>
<span class="Bold">High   blood pressure</span>.    Your blood pressure should be checked regularly and any high blood   pressure should be treated while you are taking Iclusig.  Tell your healthcare   provider if you get <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or shortness of   breath.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>).</span> Symptoms include sudden stomach-area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Your healthcare provider should do blood tests to check for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> during treatment with Iclusig.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>. </span>Iclusig may cause damage to the nerves in your arms, brain, hands, legs, or feet (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>). Tell your healthcare provider if you get any of these symptoms during treatment with Iclusig:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and loss of feeling in your hands and feet</li>
<li><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span> and other problems with eye sight, trouble moving the eye, drooping of part of the face, sagging or drooping eyelids</li>
</ul>
</li>
<li>
<span class="Bold">Effects on the eye.  </span>Serious eye problems that can lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> may happen with Iclusig. Tell your healthcare provider if you get any of the following symptoms: perceived flashes of light, light sensitivity, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">floaters</span>, dry or <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">itchy eyes</span>, and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>. Your healthcare provider will monitor your vision before and during your treatment with Iclusig.</li>
<li>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</span> Iclusig can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your healthcare provider if you get any signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while taking Iclusig including:			<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> blood or if your vomit looks like coffee-grounds</li>
<li>pink or brown urine</li>
<li>red or black (looks like tar) stools</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood or blood clots</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> of your skin</li>
<li>menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is heavier than normal</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleeds</span> that happen often</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or difficulty being awakened</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>change in speech</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>. </span>Your body may hold too much fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>). Tell your healthcare provider right away if you get any of these symptoms during treatment with Iclusig: <ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands, ankles, feet, face, or all over your body</li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
</ul>
</li>
<li>
<span class="Bold">Low blood cell counts.  </span>Iclusig may cause low blood cell counts. Your healthcare provider will check your blood counts regularly during treatment with Iclusig.  Tell your healthcare provider right away if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or any signs of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while taking Iclusig.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> (TLS).  TLS </span>is caused by a fast breakdown of cancer cells. TLS can cause you to have:		<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and the need for dialysis treatment</li>
<li>an abnormal heartbeat</li>
</ul>Your healthcare provider may do blood tests to check for TLS.</li>
<li>
<span class="Bold">Possible <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing problems.</span>  If you need to have a surgical procedure, tell your healthcare provider that you are taking Iclusig. You should stop taking Iclusig at least 1 week before any planned surgery.</li>
<li>
<span class="Bold">A tear in your stomach or intestinal wall (perforation).</span>  Tell your healthcare provider right away if you get:	<ul class="Circle">
<li>severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach-area (abdomen)</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the abdomen</li>
<li>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
</ul>
</li>
</ul>
<p><span class="Bold">The most common side effects of Iclusig include:</span></p>
<table class="Noautorules" width="70%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
<li>stomach-area (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span></li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
</ul></td>
</tr></tbody>
</table>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of Iclusig. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Iclusig?</span></p>
<p>Store Iclusig at room temperature between 68°F to 77°F (20°C to 25°C).</p>
<p><span class="Bold">Keep Iclusig and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about Iclusig</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Iclusig for a condition for which it was not prescribed. Do not give Iclusig to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>You can ask your healthcare provider or pharmacist for information about Iclusig that is written for health professionals.</p>
<p>For more information, go to www.iclusig.com or call 1-855-552-7423.</p>
<p><span class="Bold">What are the ingredients in Iclusig?</span></p>
<p><span class="Bold">Active ingredient:</span> ponatinib</p>
<p><span class="Bold">Inactive ingredients:</span> lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type B), colloidal silicon dioxide and magnesium stearate.  The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol and titanium dioxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:<br>ARIAD Pharmaceuticals, Inc.<br>26 Landsdowne Street<br>Cambridge, MA 02139-4234</p>
<p>Revised: December 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 15 mg Bottle Label</span></p>
<p>NDC 76189-535-80</p>
<p><span class="Bold">ICLUSIG</span><span class="Sup">®</span><br><span class="Bold">(ponatinib) tablets</span></p>
<p><span class="Bold">15 mg<br>Rx only</span></p>
<p>Each tablet contains ponatinib HCl<br>equivalent to 15 mg ponatinib</p>
<p><span class="Bold">Dispense Attached Medication Guide</span></p>
<p>180 Tablets<br>ARIAD<span class="Sup">®</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=807f988e-117b-4497-934d-73aa78baac71&amp;name=iclusig-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 45 mg Bottle Label</span></p>
<p>NDC 76189-534-90</p>
<p><span class="Bold">ICLUSIG</span><span class="Sup">®</span><br><span class="Bold">(ponatinib) tablets</span></p>
<p><span class="Bold">45 mg<br>Rx only</span></p>
<p>Each tablet contains ponatinib HCl<br>equivalent to 45 mg ponatinib</p>
<p><span class="Bold">Dispense Attached Medication Guide</span></p>
<p>90 Tablets<br>ARIAD<span class="Sup">®</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 45 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=807f988e-117b-4497-934d-73aa78baac71&amp;name=iclusig-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ICLUSIG 		
					</strong><br><span class="contentTableReg">ponatinib hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76189-535</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ponatinib hydrochloride</strong> (ponatinib) </td>
<td class="formItem">ponatinib</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type B potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76189-535-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76189-535-80</td>
<td class="formItem">180  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:76189-535-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203469</td>
<td class="formItem">12/14/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ICLUSIG 		
					</strong><br><span class="contentTableReg">ponatinib hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76189-534</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ponatinib hydrochloride</strong> (ponatinib) </td>
<td class="formItem">ponatinib</td>
<td class="formItem">45 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type B potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76189-534-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76189-534-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203469</td>
<td class="formItem">12/14/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ARIAD Pharmaceuticals, Inc.
							(786227231)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ash Stevens Inc.</td>
<td class="formItem"></td>
<td class="formItem">051630135</td>
<td class="formItem">ANALYSIS(76189-535, 76189-534), API MANUFACTURE(76189-535, 76189-534)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Metrics Inc.</td>
<td class="formItem"></td>
<td class="formItem">867220261</td>
<td class="formItem">ANALYSIS(76189-535, 76189-534)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Micron Technologies</td>
<td class="formItem"></td>
<td class="formItem">015966157</td>
<td class="formItem">ANALYSIS(76189-535, 76189-534)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions</td>
<td class="formItem"></td>
<td class="formItem">014167995</td>
<td class="formItem">ANALYSIS(76189-535, 76189-534)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane, Inc.</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">ANALYSIS(76189-535, 76189-534), MANUFACTURE(76189-535, 76189-534), PACK(76189-535, 76189-534)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sharp Corporation</td>
<td class="formItem"></td>
<td class="formItem">143696495</td>
<td class="formItem">PACK(76189-535, 76189-534), LABEL(76189-535, 76189-534)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Haupt Pharma Amareg GmbH</td>
<td class="formItem"></td>
<td class="formItem">331334909</td>
<td class="formItem">ANALYSIS(76189-535, 76189-534)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>853bcdc0-4a8c-4264-9fa9-faa9d4b55623</div>
<div>Set id: 807f988e-117b-4497-934d-73aa78baac71</div>
<div>Version: 7</div>
<div>Effective Time: 20141007</div>
</div>
</div> <div class="DistributorName">ARIAD Pharmaceuticals, Inc.</div></p>
</body></html>
